Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5T6US)

• Drug Name: Estrone Drug Info
• Synonyms: Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Menopausal and postmenopausal disorder	GA30	Approved	[2]

• Therapeutic Class: Antimenopausal Agents
• Cross-matching ID:
  PubChem CID: 5870
  ChEBI ID: CHEMBL1405
  CAS Number: CAS 53-16-7
  TTD Drug ID: DM5T6US
  VARIDT Drug ID: DR00494
  INTEDE Drug ID: DR0648

Molecule-Related Drug Atlas

Drug(s) Targeting Estrogen receptor (ESR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[3]
Estradiol Valerate	DM8MC6O	Hormone replacement therapy	8E01	Approved	[21]
Estradiol Acetate	DM07U2A	Hormone replacement therapy	8E01	Approved	[21]
Estradiol Cypionate	DM27Z5T	Hormone replacement therapy	8E01	Approved	[21]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[22]
Raloxifene	DMDKF3M	Osteoporosis	FB83.0	Approved	[23]
Ospemifene	DMC4GEI	Dyspareunia	GA12	Approved	[24]
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[25]
Mestranol	DMG3F94	Contraception	QA21	Approved	[26]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[29]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[30]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[33]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[34]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[35]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[36]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[40]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[35]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[42]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[43]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[44]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[46]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[47]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[40]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[49]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[50]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[51]

Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[52]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[54]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[55]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[49]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[56]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[57]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[58]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[59]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[60]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[61]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[62]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[63]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[65]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[66]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[68]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[69]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[64]

Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[70]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[71]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[73]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[74]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[49]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[75]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[76]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[77]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[78]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[79]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[80]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[11]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[75]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[81]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[75]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[82]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[84]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[85]

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[86]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[75]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[87]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[88]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[89]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[90]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[91]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[92]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]

Drug(s) Metabolized By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[94]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[54]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[49]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[57]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[95]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[96]
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[97]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[98]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[97]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[99]

Drug(s) Metabolized By Lauric acid omega-hydroxylase (CYP4A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[100]

Drug(s) Metabolized By Peroxisomal multifunctional enzyme 2 (HSD17B4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[12]

Drug(s) Metabolized By Farnesol dehydrogenase (AKR1B15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[13]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[13]
Nitrobenzaldehyde	DM4UHB5	N. A.	N. A.	Investigative	[101]

Drug(s) Metabolized By Estradiol 17-beta-dehydrogenase 2 (HSD17B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[12]

Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[12]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[105]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[106]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[107]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[109]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]

Drug(s) Affected By 3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 (HSD17B7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[111]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[119]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[120]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[121]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[123]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[124]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[125]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[126]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[127]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[128]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[129]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[127]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[130]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[130]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[131]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[132]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[133]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[134]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[136]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[137]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[138]

Drug(s) Affected By E3 ubiquitin-protein ligase SIAH2 (SIAH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[139]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[141]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[142]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[142]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[142]

Drug(s) Affected By Carbonic anhydrase 12 (CA12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[144]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[145]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[147]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[148]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]

Drug(s) Affected By Tyrosine-protein kinase JAK2 (JAK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[150]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[151]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[152]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[153]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[154]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[155]

Drug(s) Affected By monooxygenase MICAL2 (MICAL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[156]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]

Drug(s) Affected By Serine protease 23 (PRSS23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[158]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[160]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[161]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]

Drug(s) Affected By Supervillin (SVIL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[158]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[163]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[164]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[165]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[166]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]

Drug(s) Affected By Monoacylglycerol lipase ABHD2 (ABHD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[168]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Bortezomib	DMNO38U	Leukemia		Approved	[169]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]

Drug(s) Affected By Transcriptional activator Myb (MYB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[170]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[171]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[172]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[173]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[174]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[175]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[173]

Drug(s) Affected By Myb-related protein A (MYBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[176]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[177]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[178]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[179]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[164]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[176]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[180]

Drug(s) Affected By Ephrin-A1 (EFNA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[181]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[163]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[182]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[183]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]

Drug(s) Affected By Large neutral amino acids transporter small subunit 1 (SLC7A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[184]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[185]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[137]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[186]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[142]

Drug(s) Affected By DNA-binding protein inhibitor ID-3 (ID3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[187]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[188]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[163]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[191]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[192]

Drug(s) Affected By Four and a half LIM domains protein 2 (FHL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[158]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[160]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[108]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]

Drug(s) Affected By Cyclin-G2 (CCNG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[195]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[182]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[196]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[142]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[142]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[195]

Drug(s) Affected By Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[197]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[183]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[198]

Drug(s) Affected By Transcription factor AP-2 gamma (TFAP2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[199]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[200]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[201]

Drug(s) Affected By Serine/threonine-protein kinase Sgk3 (SGK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[146]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[160]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[168]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]

Drug(s) Affected By Inactive rhomboid protein 1 (RHBDF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[202]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[203]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[204]

Drug(s) Affected By DNA endonuclease RBBP8 (RBBP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[205]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[206]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[201]

Drug(s) Affected By Noelin (OLFM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[170]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[207]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[208]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[120]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[209]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[210]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[211]

Drug(s) Affected By Rap guanine nucleotide exchange factor-like 1 (RAPGEFL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[160]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[212]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[213]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[214]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[215]

Drug(s) Affected By RNA 3'-terminal phosphate cyclase-like protein (RCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[216]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[217]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]

Drug(s) Affected By Sex hormone-binding globulin (SHBG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[218]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Fructose	DM43AN2	Vomiting	MD90	Approved	[219]
Oxcarbazepine	DM5PU6O	Epilepsy	8A60-8A68	Approved	[220]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[221]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]
Dienestrol	DMBSXI0	Atrophic vaginitis	GA30.2	Approved	[222]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[222]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[222]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[222]

Drug(s) Affected By Gamma-enolase (ENO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[223]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[224]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[225]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[142]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[142]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[226]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[142]

Drug(s) Affected By Protein S100-P (S100P)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[227]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[228]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[229]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[139]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[230]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[106]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[231]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[108]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[232]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[233]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[234]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[235]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[236]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[237]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[238]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[239]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[240]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[241]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[242]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[233]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[243]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[244]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[245]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[232]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[132]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[246]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[235]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[236]

Drug(s) Affected By Rho GDP-dissociation inhibitor 1 (ARHGDIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[184]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[247]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[248]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[249]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[217]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[103]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[250]

Drug(s) Affected By Solute carrier family 12 member 2 (SLC12A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[251]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[226]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[217]
Furosemide	DMMQ8ZG	Congestive heart failure	BD10	Approved	[251]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[252]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[252]

Drug(s) Affected By Early growth response protein 3 (EGR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[253]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[106]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[196]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[254]

Drug(s) Affected By Methanethiol oxidase (SELENBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[255]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[217]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[203]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[252]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[252]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[256]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[257]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[258]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[259]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[260]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[261]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[262]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[263]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[264]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[265]

Drug(s) Affected By Na(+)/H(+) exchange regulatory cofactor NHE-RF3 (PDZK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[205]
Mestranol	DMG3F94	Contraception	QA21	Approved	[18]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[166]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[266]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[266]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[266]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]

Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Metyrapone	DMI7FVQ	Cushing disease	5A70	Approved	[267]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[268]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[269]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[270]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[271]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[269]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[272]

Drug(s) Affected By Sulfotransferase 4A1 (SULT4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[273]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[274]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[275]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[276]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[277]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[278]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[254]
Mononitrophenol	DM4QO9G	N. A.	N. A.	Investigative	[275]
L-thyroxine	DM83HWL	N. A.	N. A.	Investigative	[275]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[279]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[15]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[280]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[281]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[281]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[15]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[15]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[282]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[283]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[113]

Drug(s) Affected By Dehydrogenase/reductase SDR family member 11 (DHRS11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[19]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[19]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[143]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[206]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[166]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]

Drug(s) Affected By Dehydrogenase/reductase SDR family member 7 (DHRS7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[217]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[117]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[118]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[119]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[285]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[279]

Drug(s) Affected By Alkaline phosphatase, placental type (ALPP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[132]
Paricalcitol	DMYBV3G	Hyperparathyroidism	5A51	Approved	[132]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[286]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[287]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[288]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[289]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[290]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[291]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[292]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Agonist	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[6]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[7]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[8]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[11]
Estradiol 17-beta-dehydrogenase 2 (HSD17B2)	DEBMFZ8	DHB2_HUMAN	Substrate	[12]
Keto-steroid reductase (HSD17B7)	DEDMWFX	DHB7_HUMAN	Substrate	[12]
Farnesol dehydrogenase (AKR1B15)	DER0XCH	AK1BF_HUMAN	Substrate	[13]
Lauric acid omega-hydroxylase (CYP4A11)	DE2XQGW	CP4AB_HUMAN	Substrate	[11]
Peroxisomal multifunctional enzyme 2 (HSD17B4)	DEJHG19	DHB4_HUMAN	Substrate	[12]
Ketoacyl-CoA reductase (HSD17B12)	DE915QP	DHB12_HUMAN	Substrate	[14]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)	OT6EBDHM	DHB1_HUMAN	Biotransformations	[12]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)	OT3K7HY5	DHB2_HUMAN	Biotransformations	[12]
3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 (HSD17B7)	OTV7VOV3	DHB7_HUMAN	Biotransformations	[12]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Regulation of Drug Effects	[15]
Alkaline phosphatase, placental type (ALPP)	OTZU4G9W	PPB1_HUMAN	Biotransformations	[16]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[4]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[17]
Carbonic anhydrase 12 (CA12)	OT6WNFU8	CAH12_HUMAN	Gene/Protein Processing	[18]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Gene/Protein Processing	[18]
Dehydrogenase/reductase SDR family member 11 (DHRS11)	OTU3J0ZL	DHR11_HUMAN	Biotransformations	[19]

References

• [1] Estrone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2818).
• [3] Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
• [4] P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
• [5] Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110.
• [6] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [7] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [8] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [9] A transgenic mouse expressing human CYP1A2 in the pancreas. Biochem Pharmacol. 2000 Sep 15;60(6):857-63.
• [10] 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
• [11] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [12] Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
• [13] Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
• [14] Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol. 2006 Feb;20(2):437-43.
• [15] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [16] The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm Res. 1992 Apr;9(4):497-503. doi: 10.1023/a:1015840329786.
• [17] Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J Pharm Pharm Sci. 2006;9(1):133-9.
• [18] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [19] Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
• [20] Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [22] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [24] Clinical pipeline report, company report or official report of Shionogi (2011).
• [25] Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
• [26] Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9.
• [27] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [28] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [29] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [30] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [31] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [32] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [33] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [34] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [35] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [36] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [37] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [38] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [39] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [40] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [41] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [42] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [43] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [44] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [45] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [46] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [47] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [48] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [49] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [50] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [51] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [52] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [53] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [54] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [55] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [56] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [57] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [58] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [59] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [60] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [61] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [62] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [63] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [64] Drug Interactions Flockhart Table
• [65] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [66] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [67] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [68] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [69] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [70] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [71] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [72] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [73] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [74] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [75] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [76] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [77] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [78] Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
• [79] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [80] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [81] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [82] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [83] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [84] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [85] In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
• [86] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [87] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [88] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [89] Drugs that may have potential CYP2B6 interactions.
• [90] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [91] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [92] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [93] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [94] Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
• [95] Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
• [96] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [97] Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
• [98] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [99] Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
• [100] Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci. 2004 Jun;79(2):233-41.
• [101] Functional expression of novel human and murine AKR1B genes. Chem Biol Interact. 2011 May 30;191(1-3):177-84.
• [102] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [103] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [104] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [105] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [106] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [107] SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006 Oct;75(4):605-14.
• [108] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [109] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [110] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [111] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [112] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [113] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [114] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [115] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [116] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [117] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [118] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [119] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [120] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [121] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [122] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [123] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [124] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [125] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [126] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [127] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [128] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [129] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [130] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [131] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [132] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [133] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [134] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [135] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [136] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [137] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [138] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [139] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [140] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [141] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [142] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [143] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [144] Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem. 2011 Oct 13;54(19):6905-18.
• [145] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [146] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [147] Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem. 2011 Mar 10;54(5):1481-9.
• [148] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [149] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [150] The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
• [151] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [152] Paroxetine modulates immune responses by activating a JAK2/STAT3 signaling pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22464. doi: 10.1002/jbt.22464. Epub 2020 Feb 5.
• [153] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [154] Amlodipine inhibits cell proliferation via PKD1-related pathway. Biochem Biophys Res Commun. 2008 May 2;369(2):376-81. doi: 10.1016/j.bbrc.2008.02.075. Epub 2008 Feb 25.
• [155] Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. Eur J Pharmacol. 2015 Oct 15;765:188-97. doi: 10.1016/j.ejphar.2015.08.037. Epub 2015 Aug 20.
• [156] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [157] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [158] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [159] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [160] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [161] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [162] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [163] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [164] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [165] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [166] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [167] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [168] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [169] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [170] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [171] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [172] Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther. 2003 Jun;305(3):932-42. doi: 10.1124/jpet.103.049098. Epub 2003 Mar 20.
• [173] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [174] Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol Lett. 2012 Mar 25;209(3):239-45. doi: 10.1016/j.toxlet.2011.12.020. Epub 2012 Jan 8.
• [175] Thalidomide alters c-MYB and PIM-1 signaling in K-562 cells. Pharmacol Res. 2006 Aug;54(2):91-6. doi: 10.1016/j.phrs.2006.02.010. Epub 2006 Mar 8.
• [176] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [177] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [178] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [179] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [180] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [181] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [182] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [183] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [184] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [185] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [186] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [187] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [188] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [189] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [190] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [191] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [192] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [193] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [194] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [195] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [196] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [197] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [198] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [199] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [200] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [201] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [202] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [203] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [204] Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
• [205] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [206] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [207] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [208] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [209] Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004 Nov 1;112(2):200-12. doi: 10.1002/ijc.20401.
• [210] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [211] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [212] DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
• [213] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [214] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [215] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [216] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [217] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [218] Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003 Feb;67(2):93-9. doi: 10.1016/s0010-7824(02)00473-0.
• [219] Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest. 2007 Dec;117(12):3979-87. doi: 10.1172/JCI32249.
• [220] Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology. 2001 Jan 9;56(1):31-6. doi: 10.1212/wnl.56.1.31.
• [221] Testosterone or 17{beta}-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. J Endocrinol. 2011 Aug;210(2):219-29. doi: 10.1530/JOE-10-0497. Epub 2011 Jun 1.
• [222] Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and -fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27.
• [223] Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
• [224] [Toxic effects of aluminum on human embryonic cerebral neurocytes in vitro studies]. Zhonghua Yu Fang Yi Xue Za Zhi. 2000 Mar;34(2):106-8.
• [225] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [226] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [227] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [228] S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents. Leuk Res. 2005 Oct;29(10):1181-90. doi: 10.1016/j.leukres.2005.03.012.
• [229] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [230] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [231] Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts. Cancer Lett. 2018 Aug 28;430:1-10. doi: 10.1016/j.canlet.2018.04.043. Epub 2018 May 5.
• [232] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [233] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [234] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [235] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [236] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [237] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [238] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [239] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [240] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [241] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [242] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [243] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [244] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [245] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [246] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [247] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [248] [Differential proteomic expression in human liver cells stimulated by hydroquinone]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 Nov;24(11):658-61.
• [249] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [250] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [251] Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877. doi: 10.1038/s41598-018-27995-w.
• [252] Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
• [253] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [254] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [255] Selenium binding protein 1 in ovarian cancer. Int J Cancer. 2006 May 15;118(10):2433-40. doi: 10.1002/ijc.21671.
• [256] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [257] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [258] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [259] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [260] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [261] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [262] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [263] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [264] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [265] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [266] Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 2004 Feb;18(2):402-11. doi: 10.1210/me.2003-0202. Epub 2003 Nov 6.
• [267] The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305.
• [268] Organotin compounds enhance 17beta-hydroxysteroid dehydrogenase type I activity in human choriocarcinoma JAr cells: potential promotion of 17beta-estradiol biosynthesis in human placenta. Biochem Pharmacol. 2006 Apr 28;71(9):1349-57.
• [269] Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. J Cell Biochem. 2003 Jul 1;89(4):755-70.
• [270] Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
• [271] Acetaminophen Modulates the Expression of Steroidogenesis-Associated Genes and Estradiol Levels in Human Placental JEG-3 Cells. Toxicol Sci. 2021 Jan 6;179(1):44-52. doi: 10.1093/toxsci/kfaa160.
• [272] Decreased levels of H3K9ac and H3K27ac in the promotor region of ovarian P450 aromatase mediated low estradiol synthesis in female offspring rats induced by prenatal nicotine exposure as well as in human granulosa cells after nicotine treatment. Food Chem Toxicol. 2019 Jun;128:256-266. doi: 10.1016/j.fct.2019.03.055. Epub 2019 Apr 6.
• [273] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [274] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [275] Highly conserved mouse and human brain sulfotransferases: molecular cloning, expression, and functional characterization. Gene. 2002 Feb 20;285(1-2):39-47. doi: 10.1016/s0378-1119(02)00431-6.
• [276] Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS One. 2011;6(11):e27484.
• [277] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [278] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [279] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [280] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [281] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [282] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [283] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [284] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [285] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [286] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [287] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [288] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [289] The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
• [290] The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system. Biochem Pharmacol. 2005 Sep 1;70(5):762-9. doi: 10.1016/j.bcp.2005.06.012.
• [291] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [292] Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells. Biochemistry. 2007 Aug 7;46(31):8920-32. doi: 10.1021/bi7000328. Epub 2007 Jul 14.